Replies to post #2645 on Dendreon Corp fka DNDNQ

[walldiver]

Same patient population. Provenge's best responders exhibited survival comparable to CEGE's highest dose. One thing to keep in mind is experimental treatments usually perform much, much better in Phase II than they do in Phase III. Phase II trials are usually conducted at only one or two big-time trial centers where the patients get the very best medical care and attention. This GVAX Phase II was conducted at Johns Hopkins, a stellar research institution.

[Land Agent]

$50.00 offer expected before MAY lst -- HOLD HOLD HOLD -- safe sell at $50. but after MAY 15 could go to $100. before SEPT -- IMHO --

[bio_guyo]

Comparing Provenge and GVAX at this stage is like judging apples and oranges. The clinical data to date are from trials with entirely different designs. The 9901 and 9902b trials were crossover in design, so that the longest any patient in the control arm was deprived of Provenge was 6 months. GVAX, on the other hand, had 4 patients excluded from the phase II study for reasons that were not articulated in today's press release. Its phase III trial design lacks crossover, so that a group maintained on GVAX plus taxotere will be compared with the control arm receiving taxotere alone and never receiving GVAX.